Cargando…

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, alrea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cefalo, Chiara Maria Assunta, Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Sorice, Gian Pio, Mezza, Teresa, Pontecorvi, Alfredo, Giaccari, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393994/ https://www.ncbi.nlm.nih.gov/pubmed/30819210 http://dx.doi.org/10.1186/s12933-019-0828-y

Ejemplares similares

The Interplay between Immune System and Microbiota in Diabetes
por: Moffa, Simona, et al.
Publicado: (2019)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
por: Moffa, Simona, et al.
Publicado: (2023)

Effect of Vitamin D Supplementation on Obesity‐Induced Insulin Resistance: A Double‐Blind, Randomized, Placebo‐Controlled Trial
por: Cefalo, Chiara M.A., et al.
Publicado: (2018)

Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features
por: Capece, Umberto, et al.
Publicado: (2022)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Insulin Resistance Alters Islet Morphology in Nondiabetic Humans
por: Mezza, Teresa, et al.
Publicado: (2014)

Removal of Duodenum Elicits GLP-1 Secretion
por: Muscogiuri, Giovanna, et al.
Publicado: (2013)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis
por: Blasetti Fantauzzi, Claudia, et al.
Publicado: (2020)

Physical Activity and Type 2 Diabetes: In Search of a Personalized Approach to Improving β-Cell Function
por: Di Murro, Emanuela, et al.
Publicado: (2023)

A Systematic Comparison of Protocols for Recovery of High-Quality RNA from Human Islets Extracted by Laser Capture Microdissection
por: Cefalo, Chiara M. A., et al.
Publicado: (2021)

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
por: Musso, Giovanni, et al.
Publicado: (2019)

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
por: Sorice, Gian Pio, et al.
Publicado: (2021)

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload
por: Young, Sophia L., et al.
Publicado: (2021)

An update on pancreatic regeneration mechanisms: Searching for paths to a cure for type 2 diabetes
por: Soldovieri, Laura, et al.
Publicado: (2023)

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
por: Leccisotti, Lucia, et al.
Publicado: (2022)

Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes
por: Brusco, Noemi, et al.
Publicado: (2022)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

A review of sotagliflozin for use in type 1 diabetes
por: Nuffer, Wesley, et al.
Publicado: (2019)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
por: Rendell, Marc S
Publicado: (2019)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
por: Zhong, Peng, et al.
Publicado: (2023)

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality
por: Iyer, Nandhini, et al.
Publicado: (2023)

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
por: Rodbard, Helena W, et al.
Publicado: (2021)

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
por: Powell, David R, et al.
Publicado: (2019)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell, David R, et al.
Publicado: (2015)

OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
por: Kim, Inho, et al.
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis
por: Chen, Mao-Bing, et al.
Publicado: (2020)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
por: Zhou, Feifei, et al.
Publicado: (2022)

Effectiveness and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A protocol for Systematic review and Meta-analysis
por: Chen, Mao-Bing, et al.
Publicado: (2019)

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
por: Baker, Claire, et al.
Publicado: (2019)

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
por: Sridhar, Vikas S., et al.
Publicado: (2023)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4lc2kf1q62f3e3ghin8lo8576n